GRTX Galera Therapeutics
- 0.186
- -0.021-10.31%
Galera Therapeutics News
Express News | Galera Therapeutics Received A Notice Of Allowance For Its U.S Patent Application 17/378,852 Titled "Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability (To Reduce Oral Mucositis In Head-And-Neck Cancer Patients From Chemoradiation)"
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersINVO Bioscience (NASDAQ:INVO) shares increased by 93.4% to $1.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.8 million. As per the press release
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
Galera Therapeutics, (GRTX) Sees Unprecedented After-Hours Surge
Galera Therapeutics, Inc. (NASDAQ: GRTX) underwent a turbulent trading session on Thursday, experiencing a substantial 8.79% decline. However, as the closing bell rang, investors were greeted with a remarkable afterhours turnaround, witnessing the stock price surge by an extraordinary 32.14%. This unexpected market upheaval has sparked fervent speculation among industry pundits and enthusiasts regarding its ...
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SB
Galera Therapeutics GAAP EPS of -$0.10
Express News | As Of December 31, 2023, Galera Had Cash And Cash Equivalents Of $18.3M Which Is Expected To Provide Cash Runway Into Q2 Of 2025
Express News | Galera Therapeutics Q4 EPS $(0.10) Beats $(0.35) Estimate
Galera Therapeutics 4Q Loss/Shr 10c >GRTX
Galera Therapeutics 4Q Loss/Shr 10c >GRTX
Express News | On March 26, Galera Therapeutics Received Letter From Nasdaq Staff Indicating That Company Has Not Regained Compliance With Minimum Market Value Of Listed Securities-8K
Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
Galera Therapeutics(GRTX.US) 10% Shareholder Buys US$166.42K in Common Stocks
$Galera Therapeutics(GRTX.US)$ 10% Shareholder Schneid Yair purchased 932.4K shares of Common Stocks on Jan 29, 30, Feb 5, 6, 7, 8, 2024 at an average price of $0.1785 for a total value of $166.42K.So
12 Health Care Stocks Moving In Monday's After-Market Session
GainersJanux Therapeutics (NASDAQ:JANX) shares moved upwards by 64.2% to $24.8 during Monday's after-market session. The company's market cap stands at $1.1 billion. ICU Medical (NASDAQ:ICUI) stock in
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersAtreca (NASDAQ:BCEL) shares increased by 102.7% to $0.22 during Thursday's regular session. The company's market cap stands at $8.6 million. Sagimet Biosciences (NASDAQ:SGMT) stock rose 36.13%
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersExicure (NASDAQ:XCUR) shares increased by 50.0% to $0.93 during Tuesday's after-market session. The market value of their outstanding shares is at $8.0 million. Nuwellis (NASDAQ:NUWE) stock inc
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell 0.
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. • Caledonia Mining (AMEX:CMCL) is expected to report ear
Galera Therapeutics Q3 EPS $(0.33) Beats $(0.40) Estimate; Cash, Cash Equivalents And Short-term Investments Of $28.4M Are Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2025
Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 45 percent increase over losses of $(0.
Press Release: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating p
Galera Therapeutics 3Q Loss $15.1M >GRTX
Galera Therapeutics 3Q Loss $15.1M >GRTX
Analysis
Price Target
No Data
